Check4™ FAQs

Product Questions

1. What does IdentifySensors Biologics do?
IdentifySensors created the Check4™ platform, a new pathogen testing system that replaces current chemical-based tests, such as PCR and antigen tests, with new electronic nanotechnology.   

2. How is Check4™ different from all other tests?
Current diagnostics, such as PCR and antigen tests, rely on chemical-reactions that were developed 50 years ago. These tests were never intended for rapid, accurate results. And, they were certainly not created for a pandemic. The Check4™ system measures micro-electronic currents passed through pathogens, which provide precise results. The technique provides the accuracy of a PCR test and the convenance and speed of a rapid home antigen test. The system intends to soon be available to test multiple pathogens, such as flu, HIV, MRSA and Lyme.       

3. Do healthcare professionals need to administer the test?
No. Check4™ is intended to be a simple self-test, similar to a home pregnancy test. Check4™ allows consumers to test their saliva on a device that connects to a smartphone. Results appear on the app within minutes in the privacy of a user’s home. No prescriptions or mailing samples are needed. 

4. How does the test work?
Consumers receive a small, simple reader device and download the free smartphone app. A saliva sample is placed in the test cartridge, and the results appear within minutes on the app. It is intended that inexpensive replaceable cartridges will allow endless, affordable testing on each device for a wide range of infections.

5. How accurate is Check4™?
Following FDA approval, Check4™ intends to meet the gold-standard in hospital-grade molecular COVID testing with minimal false positives, such as a PCR test. This is significantly better than current home rapid tests, most of which show false positives and false negatives more than 50 percent of the time. 

6. Why does the test notify health authorities?
By law, all infectious test results must be reported to health authorities to help manage the pandemic and spreads of other infections. Check4™ is an electronic-based, self-test that fulfills legal reporting requirements automatically through smartphones and the cloud.

7. Why does the test use a smartphone app?
Chemical-based tests often rely on visual indicators. Check4™ uses an electronic circuit, which enables a digital signal to be sent to smartphones. The app then reports results to health authorities, which is required by law.

8. What if I don’t have a smartphone?
The smartphone app allows multiple users on a single reader. This enables family members who do not have smartphones to use the device and the app.

9. Do I have to buy multiple readers to test other family members?
No. A family can share the same device. The smartphone app is intended to allow multiple users so family members can share the same app and device, while interchanging different test cartridges.

10. Is the Smartphone app HIPAA compliant? What happens to my personal information?
By law, all test results must be reported to state and federal health authorities. All information collected by the IdentifySensors app is confidential and shared only with government agencies that require it. Some test results are de-identified, meaning that names are removed from the test results. All data is treated with the same high standards as secure hospital records. The app is securely encrypted and fully HIPAA compliant.

11. Can I turn off the reporting function of the app?
No. By law, all test results for contagious diseases must be reported to state, and federal health authorities. All information collected by the Check4™ app is encrypted, confidential, and follows high hospital standards for HIPAA-compliant privacy.

12. How much will the test cost?
It is intended that the reusable reader will cost $130. Each test cartridge will cost less than $25. The accuracy of the test and the low cost are intended to promote more frequent testing.

13. How can I be sure the test is accurate?
World-renowned scientists at Purdue University, who specialize in infectious diseases, have been developing and verifying the test’s accuracy for commercialization. The system is intended to be available to consumers following FDA approval, which is anticipated this year.

14. What is the problem with current rapid tests?
New CDC research shows that more than 50 percent of current rapid test results are incorrect. Most PCR tests currently in use are expensive and take days for the results. These chemical-based tests often require samples to be transported to a laboratory for results.

15. When will the test be available to consumers?
Industry-leading scientists at Purdue University who specialize in infectious diseases have been developing and verifying the test for commercialization. The test is intended to be available to consumers following FDA approval this year.

16. Where will the test be sold?
Check4™ is intended to be sold to corporations, health care organizations and government agencies, worldwide. High-volume commercial software that supports the test results are intended to be available the summer of 2021.

17. Can the test be used to minimize quarantine times?
Yes. Check4™ is intended to be fast, inexpensive and accurate, which enables frequent self-testing at home and without wait. Individuals infected with COVID-19, who quarantine at home, can self-test as often as they like to minimize quarantine times and return to their lives as soon as possible.

18. Is the test technology patented?
Yes, IdentifySensors holds several patents on various facets of the technology. Other patents are pending.

19. When will the product be available on the market?
Product development is in its final stages now. It is intended that the test will be available in 2021.

20. How long will the FDA approval process take?
Check4™ soon will be submitted for FDA approval. We cannot be sure how long that process will last, but the process typically lasts a few weeks. Check4™ also can be sold to and used by private and governmental agencies worldwide without U.S. FDA approval. 

21. What plans does the company have for the product have after the pandemic?
The unique technology enables the test to be easily modified for other pathogens, including other coronaviruses, variants, influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox, and methicillin-resistant staphylococcus Aureus (MRSA), as well as foodborne pathogens.

Pandemic Questions

22. How will this test help curb the pandemic?
The majority of COVID transmissions are spread by asymptomatic and early infections. PCR tests can take days for the results, and rapid home tests are incorrect more than 50 percent of the time. Check4™ is intended to provide immediate results with the accuracy of a PCR lab test. Check4 is the best of both tests. Experts agree that vaccines and the combination of instant and accurate testing holds the key to curbing the pandemic.  

23. How can businesses benefit from this test?
Customers and employees can be admitted into facilities more readily with more frequent testing. Offices, manufacturing facilities and restaurants, for example, can require self-tests of their employees. Sports facilities, airlines and concert halls, for example, can require fans to display their self-test results on their smartphones before entering.

24. How will the test benefit hospitals, health care facilities, and nursing homes?
The self-tests are intended to be fast, accurate and affordable. Frontline workers and nursing-home employees, for example, could test themselves, and their patients daily, and isolate positive cases. Slowing the spread of the virus can help hospitals manage the best use of their facilities.

The system's ability to rapidly test multiple infections could change the face of pathogen chemical testing to electronic-based testing. The change will reduce costs, increase speed and efficiencies and improve population health outcomes.  

Investment Questions

25. Why did you use Regulation A+ and not venture capital or other types of funding?
Regulation A+ opens investment opportunities to anyone, regardless of their wealth or income. IdentifySensors biologics wanted to offer this opportunity to everyone interested in this exciting project. IdentifySensors Biologics is particularly well-suited for Regulation A+ because of the welcoming atmosphere the company provides.IdentifySensors is also offering a Regulation D offering for this investment for larger investors. 

26. What happens now that I’ve made an investment?
IdentifySensors Biologics will communicate news regularly. Our first messages will be about processing your investment payment and issuing your shares. Beyond that, we will notify you regularly about company milestones. As a Regulation A+ company, we are required to make annual and semi-annual filings with the SEC, all of which will be available on the SEC’s EDGAR filing system. The filings include:

• Annual filings on Form 1-K, which are due each year and include audited financial statements for the previous fiscal year.
• Semi-annual filings on Form 1-SA, which will include unaudited financial statements for the previous six months.
• Form 1-U will announce important company events, such as leadership changes, a change in auditors, or certain types of capital-raising.

27. Can I invest if I am outside of the United States?
Yes. Investors around the world are welcome to invest. However, certain country restrictions might apply. Investors should consult their legal advisers about their ability to invest. Investors in Canada are prevented from investing in Regulation A+ by Canadian securities regulations.

28. How do I sell my shares?
These shares are not intended to list on a major exchange after the Regulation A+ offering. Because the shares are currently not listed on a stock exchange, there is no active market. However, these securities will not be restricted and can be freely traded to the extent any market develops for them from the date that an investor receives their shares. This is an advantage of Regulation A+ compared to other public offerings of private companies because securities regulations allow investors to sell their shares immediately. We intend to list our shares on a new Regulation A+ aftermarket listing services, which we intend to select after we complete this offering. We expect initially that there will be limited liquidity in this market. The company currently has no plans to seek listing or quotation of the securities on the NASDAQ, NYSE, or the OTC markets. In the future, the company may choose to list the company on a major public stock exchange to bring liquidity to the shares

29. Can I still invest if I am not an accredited investor?
Yes, investors of any wealth level over 18 years of age may participate in the Regulation A+ offering.

30. Do my shares have voting rights?
Yes, one vote per share.

31. Can I add shares to my initial investment?
Yes, but each new investment must be at least $300.